Skip to main content
Premium Trial:

Request an Annual Quote

BU, Seqster Partner on Traumatic Brain Injury Study

NEW YORK (GenomeWeb) – Boston University's Ryan Center for Sports Medicine & Rehabilitation has tapped a newly launched startup to supply genomic and other data for a study on traumatic brain injury.

San Diego-based Seqster, which emerged from stealth mode today, said that it will offer BU researchers access to its personal health records platform that aggregates data from institutional electronic health records, wearable devices, family history reports, and genomic sequences.

The Ryan Center is preparing a proof-of-concept study to identify biomarkers of traumatic brain injury in hopes of improving diagnosis and treatment of such injuries. The study will compare patients who have suffered concussions with non-concussed people who play contact sports.

"Seqster rapidly aggregates patient data from multiple data sources, which has the ability to enrich existing studies with more longitudinal personal health data and almost instantly populate de novo cohorts with longitudinal clinical data," principal investigator Rhoda Au of BU's Schools of Medicine and Public Health, said in a statement. "Since being introduced to Seqster’s technology in January, we have moved quickly to incorporate their platform into this study and a number of other studies that are in the planning stages."

While Seqster indicated that it plans to release a direct-to-consumer personal health record — historically a tough sell — its initial focus is on selling its product to provider organizations to offer to their patients, the company said.

The company has raised more than $4 million in seed financing and plans a Series A investment round to support the consumer launch. Co-founder Ardy Arianpour will serve as the company's CEO, while co-founders Xiang (Sean) Lee and Dana Hosseini will serve as chief technology officer and chief innovation officer, respectively.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.